Market Access Capping the cost of insulin: altruistic or strategic? The price of insulin has become one of the most talked about issues across the pharma industry.
News Twitter trolls, Musk's changes tank stocks for Lilly, other ... Elon Musk's Twitter takeover has been nothing if not tumultuous, and that tumult hit home for pharma Thursday, when an account impersonating Eli Lilly and Company - taking advantage of lax
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.